ArticleThe Lancet regional health. Southeast Asia2026
Pneumococcal meningitis among hospitalised children after introduction of pneumococcal conjugate vaccine in India: a sentinel hospital surveillance (2019-2022).
Article in The Lancet regional health. Southeast Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
82 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In 2017 India introduced the 13-valent pneumococcal conjugate vaccine (PCV13; Prevenar 13®) in select high-burden sites and in 2021, transitioned to nationwide introduction of 10-valent PCV (PCV10-SII; PNEUMOSIL®). We examined data from a large sentinel paediatric meningitis surveillance network to assess early changes in pneumococcal meningitis among hospitalised children after introduction of pneumococcal vaccine. Methods: Children (1-59 months) who were hospitalised with suspected meningitis at 32 hospitals across 19 states of India were enrolled in this hospital-based surveillance from 2019 to 2022. Clinical and demographic data were collected. Cerebrospinal fluid (CSF) samples were tested for Findings: Among 12,971 children enrolled, 303 (2.3%) had pneumococcal meningitis; 65.3% were between 1 and 11 months of age, and 60.1% were males. Among 260 children with outcome data, 93.1% recovered, while 6.9% died during hospitalisation. The proportion of children with pneumococcal meningitis decreased from 3.5% pre-PCV to 1.8% during both early- and post-PCV periods. Among serotyped pneumococcal meningitis, the proportion of PCV10-SII serotypes was 41.4% in pre-PCV, 33.3% early-PCV, and 25.9% post-PCV periods. The most common PCV10-SII serotypes were 5, 14, and 6B whereas non-PCV10-SII serotypes were 18C/18B, 8, and 10F. Interpretation: Decline in the proportion of PCV10-SII serotype among paediatric pneumococcal meningitis patients represents preliminary signals of PCV impact in India. These findings provide programmatically relevant evidence to inform ongoing evaluation of PCV implementation. Continued surveillance is essential to monitor serotype distribution and pneumococcal meningitis patterns over time. Funding: Gates Foundation (OPP1188408) and the United Nations Development Programme (00101970).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.